Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
NovoCure Ltd former Chief Medical Officer Nicolas Leupin reported an open-market sale of 1,100 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share. According to the disclosure, this sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. Following this transaction, Leupin directly held 102,979 Ordinary Shares.
NovoCure Ltd reported that former Chief Executive Officer Ashley Cordova had 17,638 ordinary shares withheld on March 4, 2026 to cover tax obligations tied to vesting Restricted Stock Units. The shares were withheld by the issuer at $13.30 per share in a non-discretionary, tax-withholding disposition. After this transaction, Cordova directly owned 422,570 ordinary shares.
NovoCure Ltd reported that its General Counsel, Ben Arye Barak, received new equity awards. He was granted stock options for 73,340 ordinary shares at an exercise price of $0.00 per share, bringing his total options reported in this line to 73,340.
He also acquired 50,125 ordinary shares in the form of restricted share units at $0.00 per share, increasing his directly held ordinary shares to 242,453. The restricted share units are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the grant date, subject to his continued employment. The options are scheduled to vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date, also subject to continued employment.
NovoCure Ltd chief medical and innovation officer Uri Weinberg reported several equity transactions. He sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding tied to restricted stock unit vesting, a sale mandated by the company’s equity plan. Following this sale, he held 267,190 ordinary shares. Weinberg also received 50,125 ordinary shares as a grant of restricted share units and 73,340 stock options, both at a grant price of $0.00. The restricted share units are scheduled to vest in three equal parts on the first, second, and third anniversaries of the grant date, while the stock options vest in four equal parts on the first through fourth anniversaries, each subject to his continued employment.
NovoCure Ltd Chief Financial Officer Christoph Brackmann reported a mix of equity grants and a small mandated share sale. He received 55,137 ordinary shares as a restricted stock award, which are scheduled to vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment.
He was also granted options over 80,674 ordinary shares, vesting in equal parts on the first through fourth anniversaries, subject to continued employment. In connection with restricted stock unit vesting, he sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement, leaving 182,842 ordinary shares held directly afterward.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a mix of equity awards and a small share sale. He received a grant of 150,000 ordinary shares in the form of restricted share units that vest in three equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. He also received stock options for 216,388 ordinary shares that vest in four equal parts on the first through fourth anniversaries of the grant date, also subject to continued employment. To cover tax withholding obligations from restricted stock unit vesting, he sold 5,607 ordinary shares in a mandated “sell to cover” transaction at a weighted average price of $13.3054 per share, executed in multiple trades between $13.21 and $13.445. Following these transactions, he directly holds 493,793 ordinary shares and 216,388 stock options.
NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported a combination of equity grants and share sales. On March 3, 2026, he received 45,112 Ordinary Shares as a grant, described as restricted share units that vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment. On the same date, he was granted stock options over 7,518 Ordinary Shares and 58,488 Ordinary Shares, with these options scheduled to vest in equal parts on the first, second, third and fourth anniversaries of the grant date, also conditioned on continued employment.
Subsequently, Mukund executed open-market sales of 5,377 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share and 43,246 Ordinary Shares on March 5, 2026 at a weighted average price of $13.7740 per share. A footnote states that the number of shares sold was required to cover tax withholding obligations related to the vesting of restricted stock units and was mandated by NovoCure's award agreement as a "sell to cover" transaction, rather than a discretionary trade. After the March 5 sale, Mukund directly held 72,832 Ordinary Shares.
NovoCure Ltd's Chief Human Resources Officer, Michal Nath Puri, reported equity compensation and a related tax sale. On March 3, 2026, he received 40,100 ordinary shares as restricted share units that vest over three years and 58,672 stock options vesting over four years. On March 4, 2026, he sold 1,100 ordinary shares at a weighted average price of $13.3054 in a mandated “sell to cover” transaction to satisfy tax withholding, and held 201,322 ordinary shares directly afterward.
NovoCure Ltd Executive Chairman William F. Doyle reported multiple equity compensation transactions on March 3, 2026. He received stock options for 258,445 shares and an additional option grant for 30,072 shares, which are scheduled to vest in equal parts over four years, subject to continued employment.
On the same date, he acquired 200,000 ordinary shares from restricted share units that vest over three years and 200,284 ordinary shares from performance-based restricted stock units that vested. He then sold 50,557 and 21,330 ordinary shares at weighted average prices of $12.7865 and $13.4288 to cover tax withholding obligations under a mandatory “sell to cover” provision, leaving 328,397 ordinary shares held directly.
Mukund Paravasthu reported sales of Common stock using Morgan Stanley Smith Barney LLC as broker. The filing lists four transactions dated 01/11/2026, 02/27/2026, 03/02/2026, and 03/04/2026 showing share amounts and aggregate proceeds for each sale.
The amounts reported are 2,133 shares for $30,608.55, 1,555 shares for $21,247.21, 408 shares for $5,505.14, and 5,377 shares for $71,543.14, all listed as Common stock on NASDAQ and described as securities to be sold under restricted stock vesting entries.